Cytokinetics, Incorporated
HealthcareNASDAQ:CYTK · NASDAQ Global Select
+$0.88 today
Vol 1.24M · Avg 2.39M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
119.0%
avg 127.3%
ROIC
-47.7%
avg -35.6%
ROA
-55.1%
avg -37.0%
Analysis
ROE is currently the strongest return metric at 119.0% versus its period average of 127.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert I. Blum | Chief Executive Officer, President & Director | $1.64M | — | 62 | $10,184.00 | <0.01% |
Fady Ibraham Malik FACC | Executive Vice President of Research & Development | $985,448.00 | — | 62 | $44,386.00 | 0.04% |
Andrew Callos | Executive Vice President & Chief Commercial Officer | $902,885.00 | — | 57 | $73,555.00 | 0.06% |
Sung H. Lee | EVP & CFO | $886,048.00 | — | 56 | $63,221.00 | 0.05% |
Jeffrey J. Hessekiel | Executive Vice President, Chief Legal & Administrative Officer | $286,204.00 | — | 57 | $107,943.00 | 0.09% |
James H. Sabry | Co-Founder & Chairman of Scientific Advisory Board | $41,500.00 | — | 68 | $4,301.00 | <0.01% |
James A. Spudich | Co-Founder & Member of Scientific Advisory Board | $21,938.00 | — | 84 | $4,301.00 | <0.01% |
Jeff Lotz | Vice President of Sales & Operations | — | — | — | — | — |
Holly Laughlin | Vice President of Accounting & Corporate Controller | — | — | — | — | — |
Steven Cook | Senior Vice President of Global Supply Chain Operations & Technical Operations | — | — | 67 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
60
$31.47M
Net Sentiment
$31.47M
Net selling
Most Active
Callos Andrew
22 transactions
1–10 of 60
Analysis
Insiders reported 0 buys worth $0.00 and 60 sells worth $31.47M over the last 12 months. That adds up to net selling of $31.47M. Callos Andrew was the most active insider with 22 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A12 analysts |
| Revenue | N/A | N/A | +55.9% | +34.0% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at +55.9% over three years. Forward estimates point to Revenue at +34.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.48B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.13B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.90B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Metsera, Inc.
MTSR
$7.43B
Merus N.V.
MRUS
$6.83B
Abivax S.A.
NASDAQ:ABVX
$6.33B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.06B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
Who manages CYTK?
Cytokinetics, Incorporated (CYTK) lists 10 active executives. The top listed executive is Fady Ibraham Malik FACC, Executive Vice President of Research & Development.
Are CYTK insiders buying or selling?
Recent insider activity shows net selling of $16.56M.
Explore More
Continue the stock analysis
Jump to another research area for this company.